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Background: Methamphetamine use can produce symptoms almost indistinguishable from 
schizophrenia. Distinguishing between the two conditions has been hampered by the lack of a 
validated symptom profile for methamphetamine-induced psychiatric symptoms. We use data from a 
longitudinal cohort study to examine the profile of psychiatric symptoms that are acutely exacerbated 
by methamphetamine use. 
Methods: 164 methamphetamine users, who did not meet DSM-IV criteria for a lifetime primary 
psychotic disorder, were followed monthly for one year to assess the relationship between days of 
methamphetamine use and symptom severity on the 24-item Brief Psychiatric Rating Scale. 
Exacerbation of psychiatric symptoms with methamphetamine use was quantified using random 
coefficient models. The dimensions of symptom exacerbation were examined using principal axis 
factoring and a latent profile analysis. 
Results: Symptoms exacerbated by methamphetamine loaded on three factors: positive psychotic 
symptoms (suspiciousness, unusual thought content, hallucinations, bizarre behavior); affective 
symptoms (depression, suicidality, guilt, hostility, somatic concern, self-neglect); and psychomotor 
symptoms (tension, excitement, distractibility, motor hyperactivity). Methamphetamine use did not 
significantly increase negative symptoms. Vulnerability to positive psychotic and affective symptom 
exacerbation was shared by 28% of participants, and this vulnerability aligned with a past year DSM-
IV diagnosis of substance-induced psychosis (38% vs. 22%, χ2 (df  1) = 3.66, p = 0.056).    
Conclusion: Methamphetamine use produced a symptom profile comprised of  positive psychotic and 
affective symptoms, which aligned with a diagnosis of substance-induced psychosis, with no evidence 
of a negative syndrome.  
 






Methamphetamine and amphetamine (hereafter referred to collectively as methamphetamine) can 
produce a transient psychosis almost indistinguishable from acute paranoid schizophrenia (Angrist et 
al., 1974; Angrist & Gershon, 1970; Connell, 1966; McKetin et al. 2013). Differentiating between the 
two conditions with the existing diagnostic criteria is difficult based on presenting symptoms, 
resulting in misdiagnosis, suboptimal follow-up with a potentially poorer prognosis (Mathias et al., 
2008). Given that around 30% of people diagnosed with methamphetamine-induced psychosis will be 
re-diagnosed with a schizophrenia spectrum disorder within 8 years (Niemi-Pynttari et al., 2013), 
reliable and validated  symptom assessments are critical to minimizing initial errors and identifying 
whether transition to a primary psychotic disorder occurs. However, a validated symptom profile for 
methamphetamine-induced psychiatric symptoms is currently lacking. 
  
A diagnosis of methamphetamine-induced psychosis is based on the DSM 5 criteria for substance-
induced psychosis, which stipulates the presence of either delusions and/or hallucinations (American 
Psychiatric Association, 2013). Consistent with these criteria, most studies have noted the prominence 
of hallucinations and delusions, which are usually persecutory in nature (Akiyama, 2006; Angrist et 
al., 1974; Angrist & Gershon, 1970; Chen et al., 2003; Connell, 1966; Dore & Sweeting, 2006; Harris 
& Batki, 2000; Iwanami et al., 1994; Janowsky & Risch, 1979; Mahoney et al., 2008; Medhus et al., 
2013; Srisurapanont et al., 2003).  However, they fail to distinguish between methamphetamine-
induced psychosis and schizophrenia on the remaining symptoms of schizophrenia (Hides et al., 2015; 
Medhus et al., 2013; Srisurapanont et al., 2003; Srisurapanont et al., 2011), disorganized speech (e.g. 
frequent derailment or incoherence), grossly disorganized or catatonic behavior, and negative 
symptoms (e.g. diminished emotional expression or avolition) (American Psychiatric Association, 
2013).  Many studies report affective symptoms in methamphetamine-induced psychosis, including 
depressed mood (Akiyama, 2006; Hides et al., 2015; Iwanami et al., 1994), suicidal ideation 
(Akiyama, 2006), mania (Hides et al., 2015) and hostility (Akiyama et al., 2011; McKetin et al., 
2008), but it is not clear whether these are core symptoms in methamphetamine psychosis or 
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contemporaneous phenomena. Srisurapanont et al. (Srisurapanont et al., 2011) found evidence of a 
positive syndrome (delusions, hallucinations and incoherent speech), a negative syndrome (poverty of 
speech, psychomotor retardation and flattened/incongruous affect) and an anxiety/depression 
syndrome (Srisurapanont et al., 2011), similar to that seen in people diagnosed with schizophrenia 
(Srisurapanont et al., 2011).  
 
A key challenge is disentangling psychiatric symptoms caused by methamphetamine from those due 
to pre-existing psychiatric disorders (Mathias et al., 2008). Up to half of regular methamphetamine 
users have a comorbid psychiatric disorder, including 40% with major depression and 20% with a 
primary psychotic disorder (Glasner-Edwards et al., 2008; Hides et al., 2015; McKetin et al., 2011). 
Symptoms from these disorders can conflate the psychiatric symptom profile seen in people who use 
methamphetamine, making it difficult to identify diagnostic boundaries when making cross-sectional 
comparisons of symptom profiles. Excluding people with primary disorders does not fully address this 
problem because of the difficulty distinguishing between primary and substance-induced conditions 
(Mathias et al., 2008), and because participants may experience some pre-existing symptoms without 
fully meeting criteria for a primary disorder.   
 
An alternative way to document what symptoms are induced by methamphetamine use is to examine 
which symptoms show a dose-related exacerbation during periods of methamphetamine use.  
Accordingly, we tracked the temporal concordance between level of methamphetamine use and 
psychiatric symptom severity in a longitudinal cohort of methamphetamine users who did not meet 
diagnostic criteria for a primary psychotic disorder. First, we examined the extent to which 24 
psychiatric symptoms were exacerbated in a dose-related way with increasing methamphetamine use 
(with days of use as an indicator of methamphetamine dose). We then examined the factor structure of 
this symptom exacerbation to see whether it aligned with previously conceived notions of a positive 
syndrome, a negative syndrome and an anxiety/depressive syndrome. Finally, we used a latent profile 
analysis to see whether vulnerability to the identified symptom syndromes occurred in the same 
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people, as would be expected if they reflected an underlying disorder. We also examined this latent 
symptom profile against a diagnosis of methamphetamine psychosis made using the Psychiatric 
Research Interview for DSM-IV Substance and Mental Disorders (PRISM-IV). 
 
2 METHOD 
2.1 Participants and procedure 
Participants (N = 164) were methamphetamine users from the community who did not meet DSM-IV 
criteria for a lifetime primary psychotic disorder, assessed using the PRISM-IV Version 6 (Hasin et 
al., 1996). They were volunteers who self-identified as regular (monthly) methamphetamine users 
who were recruited through needle and syringe programs, word of mouth, and  advertisements in 
magazines from Brisbane (n = 92), Melbourne (n = 49) and Sydney (n = 23), Australia (Hides et al., 
2015). We excluded 24 participants who had a lifetime primary psychotic disorder, 7 who were not 
followed up, 4 who did not report methamphetamine use at follow-up, and 2 who had missing data on 
covariates. Participants provided informed consent prior to participation and they were reimbursed up 
to $30 AUD per interview; they were at least 18 years old, understood English and were willing to 
participate in follow-up interviews. The study received approval from the Griffith University Human 
Research Ethics Committee and this approval was ratified by other participating institutions. 
 
At baseline, a face-to-face interview obtained psychiatric diagnoses, demographics, psychiatric and 
drug use history. Follow-up assessments of substance use and psychiatric symptom severity in the 
past month were undertaken monthly for one year (11 follow-ups in total). Follow-up interviews were 
conducted face-to-face at a mutually convenient location (e.g., at local health centres, cafes) or by 
phone where face-to-face interviews were not practical. Interviewers were psychology graduates who 




Participants completed a median of 11 follow-ups (range 1 to 11), with the majority of participants 
completing either 10 (22%) or all 11 follow-ups (57%). Psychiatric assessment data were complete for 
78% of participants at follow-up (7-18% per follow-up were missing). There was no significant 
relationship between loss to follow-up and average days of methamphetamine use across the follow-
up period (rs = 0.0002, p = 0.9918), meeting the maximum likelihood estimate assumption of data that 
were missing at random.  
 
2.2 Measures 
Diagnoses: DSM-IV diagnoses were made using the PRISM-IV (Hasin et al., 1996), the best 
instrument currently available to reliably differentiate between substance-induced and other psychotic 
disorders (kappa 0.70-0.83) (Torrens et al., 2004). The researchers were trained in the use of the 
PRISM by LH, an accredited user.  Episodes of major depression and mania were identified using the 
Mini International Neuropsychiatric Interview Version 5.0.0  (Lecrubier et al., 1997) which has good 
validity against structured clinical interviews (kappas of 0.84 and 0.73 respectively) (Sheehan et al., 
1997).  
 
Substance use: Days of methamphetamine use and other substance use in the past month were 
assessed using the Time-Line Follow-Back (TLFB). The TLFB is a validated measure of substance 
use (Fals-Stewart et al., 2000) which has 88% sensitivity, 96% specificity, a 95% hit-rate and 0.77 
test-retest agreement for the use of amphetamines in the past 30 days (Fals-Stewart et al., 2000). 
Other substance use was coded as: (1) cannabis use (0, 1-15, 16+ days); (2) alcohol use (0, 1-15, 
16+ days); (3) other stimulant use in the past month; (4) antidepressant use in the past month; and, (5) 
benzodiazepine use in the past month. 
 
Psychiatric symptom severity: The Brief Psychiatric Rating Scale (BPRS) (Lukoff et al., 1986) was 
used to assess the severity of 24 psychiatric symptoms during the past month on a scale of 1 (not 
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present) to 7 (extremely severe) (Lukoff et al., 1986). The BPRS yields inter-rater reliability of 0.83 
(Ventura et al., 1993) and this was 0.97 for the total BPRS score in the larger cohort from which this 
sample was drawn (Hides et al., 2015).  
 
Other measures: Psychiatric history was assessed with the Interview for the Retrospective Assessment 
of the Onset and Course of Schizophrenia and Other Psychoses (Hafner et al., 1992). Age of onset for 
alcohol and other drug use was collected from the PRISM. Demographics included age, gender, 
education, marital status, immigrant status, ethnicity and employment.  
 
2.3 Analysis    
Data were analyzed using Stata SE version 12.1 (Stata Corporation, 2014). All tests were two-sided 
with significance set at p < .05.  Group comparisons were made using a Pearson’s Chi Square test for 
categorical measures and t-tests for continuous measures. Spearman rank correlations were used. 
 
The relationship between methamphetamine use and psychiatric symptom severity was examined 
using random intercept regression models, with the time-varying BPRS item score for each month as 
the outcome variable and the time-varying number of methamphetamine-use days for each month as 
the predictor variable. We then included a random coefficient term for days of methamphetamine use 
in each model, from which we derived beta coefficients for each individual reflecting their change in 
BPRS item scores against days of methamphetamine use. These models adjusted for other substance 
use and also for time-invariant risk factors for psychosis (age, sex, immigrant status, family history of 
a primary psychotic disorder)(McGrath, 2007).  A Hausman test was used to confirm that there was 
no significant difference between the within-subject and between-subject effects for days of 
methamphetamine use. As BPRS item scores reflected a Poisson distribution, a Poisson regression 
model was estimated with a log link function, an unstructured correlation matrix, and a random 




Principal axis factor analysis with an oblique (oblimin) rotation was used to explore the factor 
structure of the beta coefficients derived from the above models. Latent profile analysis, in MPlus 
v7.2, was applied to the factor scores to derive substantively meaningful groups of people that were 
similar in their pattern of symptom exacerbation (Hagenaars & McCutcheon, 2002; Lazarsfeld & 
Henry, 1968; Muthén, 2004). Nested models were compared to determine the number of classes that 
provided the best model fit. The fit of models was compared by the bootstrap of the Lo-Mendell-
Rubin Likelihood Ratio Test (Lo et al., 2001), the Bayesian Information Criterion (BIC) (Yang, 2006) 





3.1 Characteristics of the sample 
Participants had a mean (SD) age of 32.3 (8.2) years, 60% were male, all were from an English-
speaking background, the majority were Caucasian (85%) and born in Australia (91%). Most were 
single, separated or divorced (74%); 38% had a trade certificate and 9% held a university degree. 
Forty six per cent had a lifetime DSM-IV substance-induced psychosis (62% within the past year), 
21% had a family history of a psychotic disorder, and 12% had ever been hospitalized for a 
psychiatric problem.  
 
The mean (SD) age of first methamphetamine use of was 19.7 (6.4) years and 88% had injected the 
drug. Participants had used methamphetamine on a mean (SD) of 10 (9) days in the past month at 
baseline. Methamphetamine use occurred during 80% of follow-up months, on a mean (SD) of 8 (8) 
days each month. Other drug use consisted primarily of cannabis (70% of months; mean (SD) of 18 
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(12) days) and alcohol (71% of months; mean (SD) of 12 (10) days), with other drug use being less 
common: 18% of months for benzodiazepines, 15% for heroin, 16% for ecstasy and 5% for cocaine.   
 
Months where antipsychotic medication and/or antidepressant medication were taken were excluded 
from the analysis to discount the acute effects of these drugs on BPRS symptom severity (217 months 
in total: 41 for antipsychotic medication, 165 for antidepressants and 11 for both). This left a total of 
1370 months of data for the analysis for the combined sample. 
3.2 The relationship between methamphetamine use and BPRS item severity 
Mean BPRS item scores over the follow-up period were low (range 1.0 – 2.6, for details see eFigure 1 
in the Supplement). Greater days of methamphetamine use were associated with more severe 
hallucinations, tension, motor hyperactivity, hostility, suspiciousness, distractibility, bizarre behavior, 
unusual thoughts, anxiety, excitement, suicidality, guilt, depression, somatic concern and self-neglect 
(Figure 1).  There was no significant relationship between days of methamphetamine use and the 
severity of remaining symptoms (p > 0.05, for details see eTable 1 in Supplement).  
 
3.3 Factor analysis of methamphetamine-related symptom exacerbation 
Beta coefficients for each individual reflecting their symptom exacerbation (increase in BPRS item 
scores with increasing days of methamphetamine use) were included in a principal factor analysis, 
which revealed three factors with eigenvalues > 1, explaining 91% of the variance (for details see 
eTable 2 in the Supplement). An oblique rotation indicated three factors (Table 1) corresponding to 
(1) an affective syndrome dominated by depression, suicidality, hostility and self-neglect (Factor 1); 
(2) positive psychotic symptoms of suspiciousness, unusual thought content and hallucinations 
(Factor 2); and, (3) symptoms reflecting the psychomotor effects of methamphetamine: motor 
hyperactivity, excitement, distractibility and tension (Factor 3). Factors 1 and 2 were highly correlated 
(rs = 0.61, p < 0.001) and neither were associated with Factor 3 (rs <  0.05). Guilt loaded on both 
Factors 1 and 2, bizarre behavior loaded on Factors 2 and 3, and tension loaded on Factors 1 and 3. 
11 
 
However, most items clearly delineated their parent latent factor. As the size and extent of cross-
loading was minimal, the three cross-loading items were retained, and factor scores were estimated 
post-rotation. 
3.4 Latent profile analysis of symptom exacerbation 
Latent profile analysis was applied to the factor scores derived from the factor analysis. A two-class 
model significantly improved model fit over a single-class model (LRT = 128.1, p < 0.001, BIC = 
1040; entropy = 0.68). Fit was further improved by the three-class model (LRT = 55.2, p < 0.001, BIC 
= 1034; entropy = 0.81), but not by the inclusion of a fourth class (LRT = 41.6, p = .162, BIC = 1045; 
entropy = 0.80). We therefore chose the three-class model as best fitting.   
 
Symptom cluster profiles for the three classes are displayed in Figure 2. Half the participants were 
reflected by the profile of Class 1, which had relatively low symptom exacerbation on all three 
symptom clusters. Class 2 participants (28%) reported greater symptom exacerbation of both the 
affective and the psychotic symptom clusters, while Class 3 participants (22%) were comparatively 
more vulnerable to the psychomotor symptom cluster. The mean coefficients for each BPRS item 
(reflecting the severity of symptom exacerbation), and mean factor scores, for each class are provided 
in eTable 3 in the Supplement. 
 
Participants who were more vulnerable to psychotic and affective symptom exacerbation (Class 2) 
showed a trend toward a higher past-year prevalence of substance-induced psychosis (38%) compared 
to participants in Classes 1 and 3 (22% each, χ2 (df  1) = 3.66, p = 0.056). Class 2 and 3 had greater 
average days of methamphetamine use over the study period than Class 1. There were no significant 






We found that methamphetamine use increased the severity of a range of psychiatric symptoms. 
Specifically, the number of days of methamphetamine use within a given month increased the severity 
of 15 BPRS item scores within that month. Symptoms exacerbated by methamphetamine use 
clustered on three dimensions: positive psychotic symptoms, affective symptoms and psychomotor 
agitation. There was no evidence that methamphetamine exacerbated other BPRS symptoms, 
including negative symptoms of psychosis. We also found evidence of a latent symptom profile that 
aligned with a diagnosis of methamphetamine psychosis, and that comprised both positive psychotic 
and affective symptoms.  
 
These findings reinforce the DSM 5 substance-induced psychosis criteria of hallucinations and 
delusions (American Psychiatric Association, 2013), and they are consistent with past research in 
showing that delusions in methamphetamine psychosis are primarily persecutory in nature (Akiyama, 
2006; Chen et al., 2003; Dore & Sweeting, 2006; Harris & Batki, 2000; Iwanami et al., 1994; 
Srisurapanont et al., 2003). The affective accompaniment to this psychosis (dominated by depression, 
suicidality, hostility and self-neglect) is not recognized in the diagnostic criteria for substance-induced 
psychosis (American Psychiatric Association, 2013) but our results are consistent with Srisurapanont 
et al. (Srisurapanont et al., 2011), who also found an affective symptom dimension, and other research 
showing elevated levels of depression among people diagnosed with methamphetamine psychosis 
relative to other users of the drug (Chen et al., 2003; Lecomte et al., 2013). These collective findings 
suggest that affective symptoms may be a core feature of the methamphetamine psychosis, perhaps 
similar to depression with psychotic features or schizoaffective disorder (Tsuang et al., 1982). 
Affective symptoms are also commonly seen in people with schizophrenia, including in the prodromal 
phase of first episode psychosis (Tandon et al., 2009), and can arise secondary to the distress caused 
by psychotic symptoms (Birchwood, 2003). Further research should elucidate whether the affective 
syndrome is more prominent in methamphetamine psychosis, or different in nature, than affective 




We found no indication that methamphetamine use increased negative symptoms, suggesting that this 
may be a way of differentiating between methamphetamine-induced psychosis and schizophrenia. 
Although the absence of a negative syndrome is inconsistent with the findings of Srisurapanont et al. 
(Srisurapanont et al., 2011), only 8% of patients in the Srisurapanont et al. study had reported 
negative symptoms.  These symptoms may have been secondary to psychosis or heavy drug use (e.g. 
due to deprivation, intoxication, or the effects of antipsychotic medication (Tandon et al., 2009)) or 
the result of misdiagnosis (i.e. patients with schizophrenia being misdiagnosed as having 
methamphetamine psychosis). Because we only examined symptom exacerbation during periods of 
methamphetamine use, we cannot discount the possibility that negative symptoms may manifest 
subsequent to methamphetamine-induced psychosis as part of a residual symptom profile (Tandon et 
al., 2009).  
 
The exacerbation of psychomotor symptoms (motor hyperactivity, excitement, distractibility and 
tension) by methamphetamine is typical of a stimulant drug. A different subgroup of people were 
vulnerable to psychomotor symptom exacerbation than were vulnerable to affective and positive 
psychotic symptoms. This  may be related to  different neural substrates underpinning the 
psychomotor and the psychogenic effects of methamphetamine (i.e. the nigrostriatal pathway and 
mesocorticlimbic pathways respectively) (Hsieh et al., 2014); and it may suggest distinct 
neuropathological mechanisms underlying  different symptom dimensions, not dissimilar to the 
emerging view that there are multiple and distinct etiological pathways underpinning different 
symptoms in psychotic disorders (McGrath et al., 2015; van Os, 2014; Zavos et al., 2014). 
 
Our approach assumes that symptoms exacerbated in a dose-related manner during periods of 
methamphetamine use are due to the drug. This assumption is a pragmatic one and not intended to 
imply a direct causal relationship. We adjusted for patterns of concurrent substance use, and a range 
of risk factors for psychosis, to reduce the possibility that these factors might account for more severe 
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psychiatric symptoms seen during periods of heavy methamphetamine use.  However, unmeasured 
factors (e.g. concurrent stressors), particularly those that co-occur with heavy methamphetamine use, 
may have contributed to the symptom exacerbation. Although we rely on self-reported 
methamphetamine use, self-report has been found to be an accurate and reliable indicator of drug use 
(Darke, 1998), and our measure of days of methamphetamine use has had excellent agreement with 
relevant biomarkers in other research (Fals-Stewart et al., 2000). 
4.1 Conclusion 
In sum, these results highlight the potential for methamphetamine use to increase the severity of a 
range of psychiatric symptoms, and the need to distinguish these symptoms from underlying 
psychiatric disorders, to avoid misdiagnosis and sub-optimal care. Whether these symptom clusters 
can be used to more accurately distinguish between methamphetamine-induced and primary psychotic 
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Table 1. Item loadings of three factors extracted from principal axis factoring with an oblique oblimin 
rotation 
 











Somatic concern 0.42   0.78 
Anxiety 0.47   0.69 
Depression 0.71   0.29 
Suicidality 0.70   0.56 
Guilt 0.45 0.34  0.52 
Hostility 0.67   0.56 
Suspiciousness  0.88  0.19 
Hallucinations  0.67  0.57 
Unusual thought content  0.89  0.22 
Bizarre behavior  0.41 0.37 0.53 
Self-neglect 0.61   0.64 
Tension 0.32  0.43 0.65 
Excitement   0.75 0.45 
Distractibility   0.61 0.57 
Motor hyperactivity   0.90 0.19 






Figure 1. Mean (SE) coefficient for methamphetamine use on each BPRS item (adjusted for other 
substance use and psychotropic medication) reflecting the change in BPRS item symptom severity 
with days of methamphetamine use 
 


















Figure 2.  
 
 
